Atavistik Bio is running the Phase 1/2 Harmony-HHT study in people with hereditary hemorrhagic telangiectasia (HHT).

Adults with a confirmed diagnosis of moderate to severe HHT based on frequent nosebleeds are eligible. Additional criteria may apply.

The trial is being conducted in the United States and globally.

Visit the Harmony-HHT study site

Study team: studydirector@atavistikbio.com